Simulations Plus and NVIDIA Partner to Accelerate AI-Driven Drug Development Modeling
Event summary
- Simulations Plus and NVIDIA launched a technical collaboration on May 6, 2026, to scale GPU-accelerated, AI-assisted modeling workflows for drug development.
- The partnership combines Simulations Plus’ scientific engines with NVIDIA’s AI infrastructure to reduce simulation runtimes and enable broader exploration of biological systems.
- Initial focus areas include next-generation scientific engines, AI-assisted workflows, and advancing quantitative systems pharmacology (QSP).
- Testing shows up to a 75% reduction in time required for end-to-end QSP modeling.
The big picture
This collaboration addresses core constraints in model-informed drug development (MIDD) by shifting from sequential to iterative, data-informed workflows. The partnership leverages NVIDIA’s life sciences ecosystem, including the BioNeMo platform, to support broader engagement and adoption. The integration of AI and GPU acceleration aims to reduce manual work and enable large-scale exploration of model structures and parameters, potentially setting a new standard for drug development efficiency.
What we're watching
- Adoption Pace
- The pace at which pharmaceutical partners adopt these capabilities in real-world drug development workflows.
- Execution Risk
- Whether Simulations Plus can sustain the 75% reduction in QSP modeling time across broader applications.
- Market Differentiation
- How this collaboration will position Simulations Plus against competitors in the model-informed drug development space.
Related topics